Overview

Extra Alirocumab in Addition to Statin Therapy in Asymptomatic Intracranial Atherosclerotic Stenosis (EAST-aICAS)

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

Summary

The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6 months of follow-up, in patients with asymptomatic intracranial artery stenosis.

Phase:

Phase 3

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Alirocumab
Atorvastatin